175 related articles for article (PubMed ID: 16227960)
1. Treatment options for androgen-independent prostate cancer.
Gulley J; Figg WD; Dahut WL
Clin Adv Hematol Oncol; 2003 Jan; 1(1):49-57. PubMed ID: 16227960
[TBL] [Abstract][Full Text] [Related]
2. [Current opinions on the treatment of androgen-independent prostate cancer].
Guan XX; Chen LB
Zhonghua Nan Ke Xue; 2006 Nov; 12(11):1021-5. PubMed ID: 17146932
[TBL] [Abstract][Full Text] [Related]
3. Vinorelbine, doxorubicin, and prednisone in androgen-independent prostate cancer.
Borden LS; Clark PE; Lovato J; Hall MC; Stindt D; Harmon M; M Mohler R; Torti FM
Cancer; 2006 Sep; 107(5):1093-100. PubMed ID: 16888761
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for prostate cancer - recent progress in clinical trials.
Kipp RT; McNeel DG
Clin Adv Hematol Oncol; 2007 Jun; 5(6):465-74, 477-9. PubMed ID: 17679921
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
Chan JS; Beer TM; Quinn DI; Pinski JK; Garzotto M; Sokoloff M; Dehaze DR; Ryan CW
BJU Int; 2008 Dec; 102(11):1601-6. PubMed ID: 18782306
[TBL] [Abstract][Full Text] [Related]
6. Pre-treatment nomogram for disease-specific survival of patients with chemotherapy-naive androgen independent prostate cancer.
Svatek R; Karakiewicz PI; Shulman M; Karam J; Perrotte P; Benaim E
Eur Urol; 2006 Apr; 49(4):666-74. PubMed ID: 16423446
[TBL] [Abstract][Full Text] [Related]
7. Advances in the management of metastatic androgen-independent prostate cancer.
Laber DA; Goetz H K; Bhupalam L
J Ky Med Assoc; 2006 Feb; 104(2):65-9. PubMed ID: 16594572
[TBL] [Abstract][Full Text] [Related]
8. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
9. State-of-the-art prostate cancer treatment and research. A report from the Cancer Institute of New Jersey.
DiPaola RS; Kumar P; Hait WN; Weiss RE
N J Med; 2001 Feb; 98(2):23-33. PubMed ID: 11221439
[TBL] [Abstract][Full Text] [Related]
10. Maximal androgen blockade for advanced prostate cancer.
Klotz L
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):331-40. PubMed ID: 18471790
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
Milecki P; Kwias Z; Martenka DJ
Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapies for non-metastatic prostate cancer: review of the literature.
Jereczek-Fossa BA; Curigliano G; Orecchia R
Onkologie; 2009 Jun; 32(6):359-63. PubMed ID: 19521126
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy.
Kibel AS; Nelson JB
Prostate Cancer Prostatic Dis; 2007; 10(2):119-26. PubMed ID: 17310261
[TBL] [Abstract][Full Text] [Related]
14. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
[TBL] [Abstract][Full Text] [Related]
15. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
Berry W; Eisenberger M
Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
[TBL] [Abstract][Full Text] [Related]
16. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials.
Priolo C; Oh WK; Loda M
IDrugs; 2009 Mar; 12(3):165-8. PubMed ID: 19333896
[TBL] [Abstract][Full Text] [Related]
17. [The study landscape for prostate cancer].
Miller K
Urologe A; 2005 Dec; 44(12):1431-4. PubMed ID: 16292461
[TBL] [Abstract][Full Text] [Related]
18. Secondary hormonal therapy for advanced prostate cancer.
Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone inhibitors in prostate cancer: a systematic analysis.
Schmid HP; Gregorin J; Altwein JE
Urol Int; 2008; 81(1):17-22. PubMed ID: 18645266
[TBL] [Abstract][Full Text] [Related]
20. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
